Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 4, 2003, Pages 615-624

  Rukshin, Vladimir ^a   Azarbal, Babak ^a   Finkelstein, Ariel ^a   Shah, Prediman K ^a   Cercek, Bojan ^a   Tsang, Vivian ^a   Kaul, Sanjay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Animal models; Antithrombotic effects; Experimental thrombosis; Platelets

Indexed keywords

D DIMER; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PADGEM PROTEIN; TIROFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTERY BLOOD FLOW; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; BLOOD FLOW VELOCITY; CONTROLLED STUDY; CORONARY STENT; DOG; DOSE RESPONSE; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS; TYROSINE;

EID: 0037379969     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200304000-00015     Document Type: Article

References (22)

1. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
2. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-61.
3. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352:87-92.
4. Tcheng JE. High dose eptifibatide (Integrilin) in elective coronary stenting: Results of the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Am Heart J. 2000; 140:181-8.
5. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338: 1498-1505.
6. The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-97.
7. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-43.
8. Gold HK, et al. Rapid and sustained coronary artery recanalization with bolus injection of rt-PA and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-77.
9. Kohmura C, Gold HK, Yasuda T, et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 1993; 13:1837-42.
10. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol. 1993;22381-9.
11. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755-9.
12. Rerkpattanapipat P, Kotler MN, Yazdanfar S. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor. Circulation. 1999;99:2965.
13. Badimon L, Turitto V, Rosemark JA, et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med. 1987;110:706-18.
14. Makkar RR, Litvack F, Eigler NL, et al. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation. 1997;95:1015-21.
15. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet lycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994;56:377-88.
16. Christopoulos C, Mackie I, Lahiri A, et al. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis. 1993;4:729-37.
17. Yeo EL, Gemmell CH, Sutherland DR, et al. Characterization of canine platelet P-selectin (CD 62) and its utility in flow cytometry platelet studies. Comp Biochem Physiol. 1993;105:625-36.
18. Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal angioplasty. Br Heart J. 1990;63:18-21.
19. Stokol T, Brooks MB, Erb HN, et al. D-dimer concentrations in healthy dogs and dogs with disseminated intravascular coagulation. Am J Vet Res. 2000;61:393-8.
20. Antman EM, Giugliano RP, Gibson CM, et al, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-32.
21. Haskel EJ, Abendschein DR. Deaggregation of human platelets in vitro by an RGD analog antagonist of platelet glycoprotein IIb/IIIa receptors. Thromb Res. 1989;56:687-95.
22. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J. 1998;19:1538-46.